Most Read Articles
Yesterday
The appropriate cutoff value in predicting combined cardiovascular outcomes in patients with type 2 diabetes (T2D) is 125 mm Hg for home morning systolic blood pressure (MSBP), suggests a new study.
01 Mar 2015
Red yeast rice extracts have been used in traditional medicine for centuries.1 In recent times, an extract from red yeast rice, Xuezhikang® (XZK), has been studied for its role in dyslipidaemia and cardiovascular disease. This review will look at some of the clinical trials that have done so.
06 Apr 2018

Female patients with coronary artery disease (CAD) have greater regression of coronary atherosclerosis than male patients despite a lower plaque burden at baseline, data from the GLAGOV trial have shown.

26 Apr 2018
Transcatheter aortic valve replacement (TAVR) in severe symptomatic aortic stenosis (AS) patients is superior to conventional surgical aortic valve replacement (SAVR) in terms of reducing life-threatening bleeding, new-onset atrial fibrillation and acute kidney injury, a recent meta-analysis has found.

Losartan reduces blood pressure in euvolemic hypertension after dialysis

24 Dec 2017
The American Heart Association has lowered the value for diagnosing hypertension to 130/80 from the previous 140/90.

Losartan at 50 mg is effective in reducing blood pressure in patients with postdialysis euvolemic hypertension, a recent study has shown.

Researchers performed a multicentre, randomized, prospective, single-blind trial including 88 postdialysis euvolemic patients with systolic blood pressure >140 mm Hg who were then randomized to receive either standard antihypertensive therapy or losartan alone or in combination with antihypertensives.

In the standard-arm group, blood pressure improved from a predialysis baseline value of 167.5±18.2 to 162.4±10.2 mm Hg after the 12-month follow-up, resulting in a significant drop of 5.1 mm Hg (p=0.003).  In comparison, blood pressure in the losartan group also significantly dropped from 168.65±16.33 mm Hg at baseline to 158.45±10.65 mm Hg after 12 months (difference, 10.23 mm Hg; p<0.001).

On the other hand, postdialysis blood pressure was only significantly improved in the losartan group, with the baseline value of 156.34±13.40 mm Hg dropping to 149.73±10.21 mm Hg after 12 months. The difference of 6.6 mm Hg reached statistical significance (p<0.001).

There were more deaths in the standard arm than in the losartan group (13.6 vs 4.5 percent), resulting in respective survival probabilities of 84 and 95 percent. However, Kaplan-Meier analysis showed no significant difference in survival between the groups.

In terms of adverse events, losartan was found to be related to two cases of hyperkalaemia, four cases of coughs, three cases of dizziness, and one case of dyspepsia.

Finally, simple linear regression showed that diabetes was significantly associated with postdialysis systolic blood pressure in both the standard-arm (p=0.03) and losartan (p=0.02) treatment groups. 

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Cardiology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Yesterday
The appropriate cutoff value in predicting combined cardiovascular outcomes in patients with type 2 diabetes (T2D) is 125 mm Hg for home morning systolic blood pressure (MSBP), suggests a new study.
01 Mar 2015
Red yeast rice extracts have been used in traditional medicine for centuries.1 In recent times, an extract from red yeast rice, Xuezhikang® (XZK), has been studied for its role in dyslipidaemia and cardiovascular disease. This review will look at some of the clinical trials that have done so.
06 Apr 2018

Female patients with coronary artery disease (CAD) have greater regression of coronary atherosclerosis than male patients despite a lower plaque burden at baseline, data from the GLAGOV trial have shown.

26 Apr 2018
Transcatheter aortic valve replacement (TAVR) in severe symptomatic aortic stenosis (AS) patients is superior to conventional surgical aortic valve replacement (SAVR) in terms of reducing life-threatening bleeding, new-onset atrial fibrillation and acute kidney injury, a recent meta-analysis has found.